544 results about "Ankylosing spondylitis" patented technology

The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of ankylosing spondylitis in a subject.

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of ankylosing spondylitis in a subject.

The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker.

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

The invention provides tools for management of patients diagnosed with ankylosing spondylitis and prior to the initiation of therapy with an anti-TNFalpha agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary end-points using serum marker concentrations. In one embodiment the baseline level of leptin or osteocalcin is used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as complement component 3.

The invention includes a method for determining the disease status of an individual suffering from ankylosing spondylitis by monitoring the individual's T-cell repertoire for the presence and/or level of clonotypes encoding T-cell receptor chains with segments identical to and/or related to the peptide LCASSLEASGSSYNEQFFGPGTRLTV (SEQ ID NO: 1) or the peptide VYFCASSDSSGSTDTQYFGPGTRLTV (SEQ ID NO: 2). The invention also includes therapeutic antibodies specific for these peptides for ameliorating the effects of ankylosing spondylitis.

The present invention relates to compounds of Formula (I),

methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The present invention relates to compounds of Formula (I),

methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention provides a flurbiprofen hydrogel plaster and a composition thereof. In the composition, the content of flurbiprofen is 0.1-3wt%, and a hydrogel substrate accounts for the rest. Based on the total weight of the hydrogel substrate, the hydrogel substrate comprises the following components: 0.1-40wt% of a hydrophilic base material, 0.01-2wt% of a crosslinking agent, 0.01-4wt% of a crosslinking regulator, 10-60wt% of a humectant, 0.05-45wt% of a penetration enhancer and 10-85wt% of a solvent. According to the flurbiprofen hydrogel plaster provided by the invention, a small number of medicines are used, and the permeability and stability are good; and the flurbiprofen hydrogel plaster can be applied to various arthralgia diseases such as rheumatic arthritis, gouty arthritis, ankylosing spondylitis, tenosynovitis, muscle pain and lumbago.

The invention discloses application of an exosome of a mesenchymal stem cell source in preparation of a drug for treating ankylosing spondylitis. The exosome of the mesenchymal stem cell source has the inhibition effect on both chronic inflammations and pathological osteogenesis and has the advantages of being low in side effect and cost and more durable in effect.

Administration of IL-21 results in decreasing autoimmune responses and thereby provides a beneficial treatment for autoimmune diseases. Specific autoimmune diseases that may be treated include multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, ankylosing spondilitis, scleroderma, Type I diabetes, psoriatic arthritis, osteoarthritis, inflammatory bowel disease, atopic dermatitis and asthma. Pharmaceutical compositions can include IL-21 polypeptides and active fragments thereof.

The invention belongs to the field of traditional Chinese medicines and particularly relates to a medicine for treating and preventing the rheumatism of muscles and bones, which comprises a medicine for oral administration and a medicine for external use, wherein the medicine for the oral administration comprises the following components: sea otter, sea horse, Rhizoma Drynariae, antler glue, Herba Epimedii, fleece-flower root, Eucommia ulmoides, large-leaved gentian, Monkshood, Angelica sinensis, Caulis Spatholobi, Astragalus mongholicus, scorpio, frankincense, myrrh, earthworm, Sweetgum Fruit, notopterygium root, Radix Saposhnikoviae, ground beetle, Manis pentadactyla, pseudo-ginseng, gastrodia elata, rhizoma corydalis and Ligusticum wallichii, and the medicine for the external use comprises the following components: Alangium platanifolium, rhizoma smilacis glabrae, semen brassicae, Eupolyphaga, monkshood, radix aconiti agrestis, phryma leptostachya and curcuma zedoary. The medicinalmaterials are soaked to prepare medicated wine by using 58-62 degrees of white spirit after being ground into powder, and the two medicines are combined for use. The medicine for treating and preventing the rheumatism of the muscles and bones has an obvious effect and especially has an obvious curative effect on the rheumatism of the muscles and bones, such as rheumatism, rheumatoid arthritis, lumbar intervertebral disc protrusion, lumbar muscle degeneration, Ankylosing Spondylitis, femoral head necrosis, arthroedema, sciatica, intermittent claudication, cervical vertebra ache and stiffness, amyotrophy, osteoproliferation, scapulohumeral periarthritis, arthritis, arthromeningitis and the like and has a wide application range, is economic and practical and is convenient to popularize.

The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided.

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl sulfonamides and related compounds (collectively referred to herein as ‘BPSAAA compounds’), as described herein, and including, for example, biphenyl-4-sulfonic acid (hydroxyalkyl-phenyl)-amides and related compounds. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment and/or prevention, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of, inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activation in rheumatoid arthritis, osteoporosis, cancer associated bone disease, Paget's disease and the like.

The invention relates to a traditional Chinese medicine composition for treating rheumatoid bone pain and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials: lycopodium clavatum, radix clematidis, cortex acanthopanacis, corydalis tuber, paniculate swallowwort root, semen momordicae, dandelion, burdock, fraxinus bungeana, caulis akebiae, sichuan lovage rhizome and the like. The traditional Chinese medicine composition has the beneficial effects that medicines in the raw materials are reasonably compatible; and the composition is an externally applied medicine, is capable of directly reaching a focus by means of transdermal absorption and quickly taking effect, has the effects of activating blood circulation to remove stasis, eliminating rheumatoid pathogenic cold, eliminating bone spur hyperplasia, dredging blood vessels, diminishing inflammation and relieving pain, has good effects of treating cervical spondylosis, lumbar disc herniation, spinal stenosis, water on the knee, ankylosing spondylitis, muscle stiffness and the like, has good curative effects on stomachache, dysmenorrhea and hyperplasia of mammary glands, and has a good effect of killing cancer cells. The preparation method is simple, easy to operate, and is capable of realizing large-scale production.

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. Formula (I).

The invention belongs to the technical field of traditional Chinese medicines and relates to a plaster for treating rheumatoid bone diseases and a preparation method thereof. The plaster for treating rheumatoid bone diseases is prepared from 45 traditional Chinese medicines of Chinese angelica, nux vomica, stiff silkworm, aconite root, radix aconite, safflower, divaricate saposhnikovia root, peach kernel, medicinal cyathula root and the like. The plaster for treating rheumatoid bone diseases is designed on the basis of a secret prescription handed down from ancestors of the inventor according to years of clinical experiences of the inventor and is prepared by repeated experiments, and thus the plaster has unique curative effects on refractory facial paralysis. The plaster for treating rheumatoid bone diseases has a reasonable and rigorous formula, and can be prepared by unique processes. Through use of the plaster for treating rheumatoid bone diseases, wry mouth, oblique eyes and facial spasm caused by facial paralysis can be cured fast. The plaster for treating rheumatoid bone diseases acts fast, and has a short treatment course, a high cure rate and a low cost. The plaster provided by the invention has unique curative effects on rheumatism, rheumatoid arthritis, back and leg pain, scapulohumeral periarthritis, numbness of limbs, sciatica, hyperostosis, lumbar disc herniation, cervical spondylosis, ankylosing spondylitis, hyperplasia of mammary glands, various stubborn pains, fracture sequelae, wry mouth and oblique eyes.

The invention provides a medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method, wherein the preparation is prepared form Chinese medicinal herbs incluing multibanded krait, black-tail snake, earthworm, buthus martensi kirsch, centipede, pangolin scales, American ginseng, dragon's blood resin, notoginseng, wood louse, batryticated silkworm, apiary, deer horn gum, root of herbaceous peony, arisaema tuber, corydalis tuber, licorice root, and borneol.

The invention discloses a method and a reagent for prediction of ankylosing spondylitis susceptibility. According to the invention, genomic DNA of a host cell is extracted and the genotype of site + 879 in a second intron zone of the AIF1 gene of a subject is determined so as to predicate susceptibility of the subject to ankylosing spondylitis; if the genotype of the single nucleotide polymorphism site + 879 is CC, lowest ankylosing spondylitis susceptibility is obtained, and if the site + 879 contains a T allele, i.e., the genotype is CT or TT, highest susceptibility is obtained. The invention has the following advantages: correlation between the AIF1 gene polymorphism site and the ankylosing spondylitis is elaborated for the first time; the method for predicting ankylosing spondylitis susceptibility is provided; and the method is applicable to prevention, auxiliary diagnosis and treatment of ankylosing spondylitis and can also be used for research and development of a novel drug.